SG11202012570TA - Oxadiazoles as agonists of the muscarinic m1 and/or m4 receptor - Google Patents
Oxadiazoles as agonists of the muscarinic m1 and/or m4 receptorInfo
- Publication number
- SG11202012570TA SG11202012570TA SG11202012570TA SG11202012570TA SG11202012570TA SG 11202012570T A SG11202012570T A SG 11202012570TA SG 11202012570T A SG11202012570T A SG 11202012570TA SG 11202012570T A SG11202012570T A SG 11202012570TA SG 11202012570T A SG11202012570T A SG 11202012570TA
- Authority
- SG
- Singapore
- Prior art keywords
- oxadiazoles
- muscarinic
- agonists
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1810245.9A GB201810245D0 (en) | 2018-06-22 | 2018-06-22 | Pharmaceutical compounds |
| PCT/GB2019/051778 WO2019243850A1 (en) | 2018-06-22 | 2019-06-24 | Oxadiazoles as agonists of the muscarinic m1 and/or m4 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012570TA true SG11202012570TA (en) | 2021-01-28 |
Family
ID=63042556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012570TA SG11202012570TA (en) | 2018-06-22 | 2019-06-24 | Oxadiazoles as agonists of the muscarinic m1 and/or m4 receptor |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10858352B2 (en) |
| EP (1) | EP3810607A1 (en) |
| JP (2) | JP7389762B2 (en) |
| KR (1) | KR20210024036A (en) |
| CN (1) | CN112585135A (en) |
| AU (1) | AU2019289216B2 (en) |
| BR (1) | BR112020026437A2 (en) |
| CA (1) | CA3104085A1 (en) |
| GB (1) | GB201810245D0 (en) |
| MX (1) | MX2020014156A (en) |
| SG (1) | SG11202012570TA (en) |
| TW (1) | TW202019918A (en) |
| WO (1) | WO2019243850A1 (en) |
| ZA (1) | ZA202007986B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201402405QA (en) | 2011-11-18 | 2014-09-26 | Heptares Therapeutics Ltd | Muscarinic m1 receptor agonists |
| GB201513743D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810245D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) * | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| AU2020361735B2 (en) * | 2019-10-09 | 2024-04-18 | Novartis Ag | 2-azaspiro(3.4)octane derivatives as M4 agonists |
| PE20221454A1 (en) * | 2019-10-09 | 2022-09-21 | Novartis Ag | 2-AZASPYRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999032486A1 (en) * | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| US7786141B2 (en) | 2004-08-19 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Dihydrospiroindene modulators of muscarinic receptors |
| KR20080087841A (en) | 2005-12-22 | 2008-10-01 | 버텍스 파마슈티칼스 인코포레이티드 | Modulators of muscarinic receptors |
| KR20080098070A (en) | 2006-02-22 | 2008-11-06 | 버텍스 파마슈티칼스 인코포레이티드 | Spiro condensed piperidines as modulators of muscarinic receptors |
| EP2051712A2 (en) | 2006-08-15 | 2009-04-29 | Vertex Pharmceuticals Incorporated | Modulators of muscarinic receptors |
| WO2008117229A1 (en) * | 2007-03-23 | 2008-10-02 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| BR112013006344A2 (en) * | 2010-09-17 | 2016-06-21 | Array Biopharma Inc | piperdinyl substituted lactams as gpr119 modulators, pharmaceutical composition comprising them, use and process for preparing same |
| US9266857B2 (en) * | 2012-09-18 | 2016-02-23 | Heptares Therapeutics Limited | Bicyclic AZA compounds as muscarinic M1 receptor agonists |
| WO2014122474A1 (en) | 2013-02-07 | 2014-08-14 | Takeda Pharmaceutical Company Limited | Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists |
| KR102352388B1 (en) | 2014-02-06 | 2022-01-17 | 헵테얼즈 테라퓨틱스 리미티드 | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists |
| GB201404922D0 (en) * | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201617454D0 (en) * | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| GB201810245D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
-
2018
- 2018-06-22 GB GBGB1810245.9A patent/GB201810245D0/en not_active Ceased
-
2019
- 2019-06-24 CN CN201980054880.1A patent/CN112585135A/en active Pending
- 2019-06-24 CA CA3104085A patent/CA3104085A1/en active Pending
- 2019-06-24 EP EP19734158.9A patent/EP3810607A1/en active Pending
- 2019-06-24 US US16/450,279 patent/US10858352B2/en active Active
- 2019-06-24 KR KR1020217001748A patent/KR20210024036A/en unknown
- 2019-06-24 JP JP2020571700A patent/JP7389762B2/en active Active
- 2019-06-24 MX MX2020014156A patent/MX2020014156A/en unknown
- 2019-06-24 BR BR112020026437-7A patent/BR112020026437A2/en unknown
- 2019-06-24 SG SG11202012570TA patent/SG11202012570TA/en unknown
- 2019-06-24 WO PCT/GB2019/051778 patent/WO2019243850A1/en active Application Filing
- 2019-06-24 TW TW108122031A patent/TW202019918A/en unknown
- 2019-06-24 AU AU2019289216A patent/AU2019289216B2/en active Active
-
2020
- 2020-10-13 US US17/069,070 patent/US11319312B2/en active Active
- 2020-12-21 ZA ZA2020/07986A patent/ZA202007986B/en unknown
-
2023
- 2023-09-22 JP JP2023158190A patent/JP2023164721A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3810607A1 (en) | 2021-04-28 |
| BR112020026437A2 (en) | 2021-03-23 |
| US11319312B2 (en) | 2022-05-03 |
| CN112585135A (en) | 2021-03-30 |
| TW202019918A (en) | 2020-06-01 |
| JP2021528447A (en) | 2021-10-21 |
| AU2019289216A1 (en) | 2021-01-14 |
| US20210101893A1 (en) | 2021-04-08 |
| AU2019289216B2 (en) | 2023-04-06 |
| MX2020014156A (en) | 2021-03-09 |
| GB201810245D0 (en) | 2018-08-08 |
| CA3104085A1 (en) | 2019-12-26 |
| WO2019243850A1 (en) | 2019-12-26 |
| JP2023164721A (en) | 2023-11-10 |
| KR20210024036A (en) | 2021-03-04 |
| US20190389849A1 (en) | 2019-12-26 |
| ZA202007986B (en) | 2021-10-27 |
| US10858352B2 (en) | 2020-12-08 |
| JP7389762B2 (en) | 2023-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202007986B (en) | Oxadiazoles as agonists of the muscarinic m1 and/or m4 receptor | |
| IL273924A (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| HK1248218A1 (en) | Spirocyclic compounds as agonists of the muscarinic m1 receptor and/or m4 receptor | |
| HK1253036A1 (en) | Oxime compounds as agonists of the muscarinic m1 and/or m4 receptor | |
| EP3810614C0 (en) | Bridged compounds as agonists of the muscarinic m1 and/or m4 receptor | |
| IL274062A (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| IL276411A (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| IL271805A (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| EP3732163A4 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| EP3697781A4 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| EP3665175A4 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| EP3762386A4 (en) | Adenosine receptor antagonists and uses thereof | |
| IL281938A (en) | Stable semaglutide compositions and uses thereof | |
| ZA202004532B (en) | Compositions for the management of hyperglycemia and related conditions | |
| IL260720B (en) | Inhibitors of the orexin-1 receptor and compositions comprising the same | |
| RS64722B1 (en) | Heterocyclic compound and its use as positive allosteric modulator of the cholinergic muscarinic m1 receptor. | |
| EP3891143C0 (en) | Quinolinone and benzoxazine derivatives as muscarinic m1 and/or m4 receptor agonists | |
| IL276814A (en) | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | |
| EP3662906A4 (en) | Agonist of 67 kda laminin receptor and utilization thereof | |
| EP3894441A4 (en) | Rank antagonists and uses therefor | |
| IL282142A (en) | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament | |
| GB201815215D0 (en) | Composition and use |